[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chen Xiaoping\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":157},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,94,120,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535186","adjuvant-pd-1-inhibitor-for-patients-with-early-stage-hepatocellular-carcinoma-following-microwave-ablation-100535186",false,"NCT06248554","Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation","Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation: a Prospective Cohort Study","Inclusion Criteria:\n\n* Aged 18-75 years\n* Pathological type is HCC, BCLC stage 0-A\n* No extrahepatic HCC\n* No radiographic recurrence at 2-4 weeks after ablation\n* Eastern Cooperative Oncology Group (ECOG) performing status of 0-1\n* Child-Pugh grade A or B and adequate hematologic and organ function\n\nExclusion Criteria:\n\n* Any history of other malignant tumors or recurrent HCC\n* Any preoperative treatment for HCC including local and systemic therapy\n* Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency\n* Any persistent serious ablation-related complications\n* Esophageal and\u002For gastric variceal bleeding within 6 months\n* Inability or refusal to comply with the treatment and monitoring\n* Participation in other clinical trials","ALL","18 Years","75 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.",[27],"Hepatocellular Carcinoma",[29,30,31,32],"Hepatocellular carcinoma","Adjuvant therapy","Microwave ablation","PD-1 inhibitor","RECRUITING","2025-11-29",{"date":36,"type":37},"2025-12-02","ACTUAL",{"date":39,"type":37},"2019-12-01",{"date":41,"type":21},"2025-12-31",{"name":43,"class":44},"Chen Xiaoping","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100548395","phase-2-neoadjuvant-therapy-in-patients-with-resectable-hcc-screened-by-a-multimodal-deep-learning-model-100548395","NCT06420440","Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model","Efficacy and Safety of Neoadjuvant HAIC Combined With Tislelizumab and Lenvatinib in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Enhanced MRI determines that the tumor is technically resectable but at high risk for recurrence(BCLC-A tumor diameter more than or equal to 5cm; BCLC-B; BCLC-C) ; without distant metastasis.\n7. Pathologic type of hepatocellular carcinoma confirmed by puncture biopsy.\n8. Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and PD-1 inhibitors.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n4. Active infection.\n5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n6. Inability to follow the study protocol for treatment or follow up as scheduled.",{"count":54,"type":21},160,[56],"PHASE2","Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.",[59],"HCC",[29,61,62,63],"Neoadjuvant tehrapy","recurrence","Deep learning","2025-04-28",{"date":66,"type":37},"2025-05-01",{"date":68,"type":37},"2024-06-01",{"date":70,"type":21},"2027-05-31",{"name":43,"class":44},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100551696","phase-1-precision-treatment-of-unresectable-hcc-guided-by-multi-omics-deep-learning-models-100551696","NCT06463444","Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models","Precision Treatment of Unresectable Liver Cancer Based on Multi-omics Deep Learning Model: a Multi-center Prospective Single-arm Study","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Enhanced MRI determines that the tumor is technically unresectable.\n7. Pathologic type of hepatocellular carcinoma confirmed by puncture biopsy.\n8. Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and PD-1 inhibitors.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n4. Active infection.\n5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n6. Inability to follow the study protocol for treatment or follow up as scheduled.",{"count":81,"type":21},30,[83],"PHASE1","Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.",[59,86],"Precision Therapy","2024-06-12",{"date":89,"type":37},"2024-06-17",{"date":68,"type":37},{"date":92,"type":21},"2026-06-30",{"name":43,"class":44},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100540061","phase-4-triple-vs-dual-adjuvant-therapy-following-liver-resection-for-hcc-100540061","NCT06311942","Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.","Effectiveness of Triple Versus Dual Adjuvant Therapy in VETC-positive Population Following Liver Resection for HCC: a Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Pathologic type is hepatocellular carcinoma .\n7. Confirmation of the presence of VETC vascular pattern by CD34 immunohistochemical staining.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n4. Active infection.\n5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n6. Inability to follow the study protocol for treatment or follow up as scheduled.",{"count":102,"type":21},300,[104],"PHASE4","Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.",[59],[59,30,108,109,110,111],"VETC","HAIC","Lenvatinib","PD-1 inhibitors","2024-05-05",{"date":114,"type":37},"2024-05-07",{"date":116,"type":37},"2024-04-01",{"date":118,"type":21},"2028-12-31",{"name":43,"class":44},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":135,"locationsCount":45},"100540060","phase-4-precision-adjuvant-therapy-after-surgery-for-hepatocellular-carcinoma-100540060","NCT06311929","Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma","VETC-based Precision Adjuvant Therapy for Postoperative Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Pathologic type is hepatocellular carcinoma.\n7. Confirmation of the presence of VETC vascular pattern by CD34 immunohistochemical staining.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n4. Active infection.\n5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n6. Inability to follow the study protocol for treatment or follow up as scheduled.",{"count":102,"type":21},[104],"Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.",[59],[59,30,108,32,110],{"date":114,"type":37},{"date":116,"type":37},{"date":118,"type":21},{"name":43,"class":44},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":4},"100540059","phase-4-efficacy-and-safety-of-neoadjuvant-therapy-in-patients-with-resectable-hcc-screened-by-a-multimodal-deep-learning-model-100540059","NCT06311916","Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.","Efficacy and Safety of Neoadjuvant HAIC Combined With Immunotherapy and Targeted Therapy in Patients With Resectable Intermediate-stage HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Enhanced MRI determines that the tumor stage is intermediate (BCLC stage B) and is safe for radical hepatectomy.\n7. Pathologic type of hepatocellular carcinoma confirmed by puncture biopsy.\n8. Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and PD-1 inhibitors.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Tumor distribution in two liver lobes, diffuse growth, or other reasons why radical R0 resection is not possible.\n3. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n4. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n5. Active infection.\n6. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n7. Inability to follow the study protocol for treatment or follow up as scheduled.",{"count":144,"type":21},312,[104],"Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). The intermediate stage (BCLC-B) HCC is highly heterogeneous, and there is no consensus on the treatment of this stage of the tumor in Western and Eastern countries. New tools are urgently needed to guide the choice of treatment options for patients with this stage of the tumor in order to reduce the risk of postoperative recurrence and the overall survival rate.",[59],[29,61,62,63],"NOT_YET_RECRUITING","2024-03-09",{"date":152,"type":37},"2024-03-15",{"date":154,"type":21},"2024-05-01",{"date":118,"type":21},{"name":43,"class":44},""]